For many advanced practitioners, patients with hematologic malignancies may present infrequently due to the rarity of occurrence. The heterogenous presentation and clinical course of these diseases, along with the fast pace of scientific discovery, creates a challenging environment for clinicians to stay up to date on clinical management. This collection of presentations provides advanced practitioners with a comprehensive overview of treatment strategies and best practices for the side-effect management of novel therapies for various hematologic malignancies.
Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Program Chair
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center
Faculty
Amy Goodrich, MSN, CRNP
Johns Hopkins School of Medicine, Kimmel Cancer Center
Faculty
Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center
Faculty
Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine
Faculty
Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center
Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents
Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 1.5
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents
Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 1.0
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
Emerging Therapies for Multiple Myeloma
Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 0.75
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
Emerging Therapies for Hodgkin Lymphoma
Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 0.50
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 1.0
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
Risk-Adapted Treatment of Acute Myelogenous Leukemia
Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 1.25
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the Annenberg Center for Health Sciences website.
These CME/CE/CPE certified activities are jointly provided by
 |
 |
 |
 |